Isomorphic Labs raises $5 billion to expand AI drug discovery

Covered by 3 sources
Read onThe Next Web· 3 min
Isomorphic Labs, an AI drug design company owned by Alphabet, has raised $5 billion in a Series C funding round led by Sequoia Capital and Greenoaks. The capital will be used to advance its AI platform, IsoDDE, accelerate clinical trials, broaden its drug development into biologics, and support partnerships with pharmaceutical firms like Eli Lilly and Novartis.

What happened

Isomorphic Labs, Alphabet’s AI-focused drug discovery company led by Demis Hassabis, raised $5 billion in a Series C funding round. The round was co-led by Sequoia Capital and Greenoaks, with participation from existing and new investors. The announcement came six months after Isomorphic Labs previously raised $2.1 billion. The company plans to use the funds to accelerate its AI-driven drug development and expand its platform.

Key details

  • The $5 billion Series C round was co-led by Sequoia Capital and Greenoaks.
  • Isomorphic Labs’ IsoDDE platform is being used in over 20 drug development programs, including partnerships with Eli Lilly, Novartis, and Johnson & Johnson.
  • The company aims to move into biologics and other drug modalities beyond small molecules.
  • Isomorphic Labs is headquartered in London, with offices in Cambridge, Massachusetts, and Lausanne.

Why it matters

Pharmaceutical companies and biotech investors are directly affected, as Isomorphic Labs’ increased funding could speed up the development of new drugs using AI. This funding gives the company resources to expand its drug pipeline and move towards clinical trials, which could impact timelines for new treatments. The partnerships with major pharmaceutical firms mean that advances from Isomorphic Labs may influence drug development strategies across the industry.

Also covered by 2 sources


More in Healthcare